Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India

被引:2
作者
Taneja, Juhi [1 ,7 ]
Chatterjee, Kuhu [1 ]
Sasidharan, Jaseetha [2 ]
Abbas, Syed Zafar [3 ]
Rai, Anil Kumar [2 ]
Raychaudhury, Sujata [4 ]
Das, Bhabatosh [5 ]
Das, Asim [6 ]
机构
[1] ESIC Med Coll & Hosp, Dept Microbiol, Faridabad, India
[2] ESIC Med Coll & Hosp, Dept ENT, Faridabad, India
[3] ESIC Med Coll & Hosp, Dept Radiol, Faridabad, India
[4] ESIC Med Coll & Hosp, Dept Pathol, Faridabad, India
[5] Translat Hlth Sci & Technol Inst, Faridabad, India
[6] ESIC Med Coll & Hosp, Faridabad, India
[7] ESIC Med Coll & Hosp, Dept Microbiol, Faridabad 121001, Haryana, India
关键词
mucormycosis; COVID-19-associated mucormycosis; rhino-orbito-cerebral mucormycosis; antifungal susceptibility; amphotericin B; MANAGEMENT; MUCOR;
D O I
10.1093/mmy/myad067
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The second wave of coronavirus disease 2019 (COVID-19), during the early 2021, lead to a devastating outbreak of mucormycosis in India. This study aimed to determine the aetiology, clinical features, comorbidities, and risk factors of rhino-orbito-cerebral mucormycosis (ROCM) and antifungal susceptibility pattern for the isolates. The study included all suspected cases of ROCM in post-COVID-19 patients attending the hospital from May to December 2021. A total of 70 patients were diagnosed with mucormycosis during the study period. The commonest presentations were rhino-orbital and rhino-orbito-cerebral in 35.7% of cases each. Diabetes mellitus was the commonest associated risk factor in 95.7% of all patients, while 78.5% of the patients were treated with corticosteroids in the recent past, and 25.7% presented with active COVID-19 pneumonia. The commonest isolate was Rhizopus arrhizus n = 14, followed by Aspergillus flavus n = 16, A. fumigatus n = 4, A. niger n = 3, Fusarium oxysporumn = 1, and Apophysomyces variabilisn = 1. Fungal species identification was done by phenotypic methods for all the isolates and DNA sequence analysis of 18 isolates, and antifungal susceptibility testing of 30 isolates was performed by commercially prepared HiMIC plate (HiMedia, Mumbai, India) using broth microdilution for amphotericin B, isavuconazole, itraconazole, voriconazole, and posaconazole. The MIC50 and MIC90 of amphotericin B for R. arrhizus strains were 0.25 and 4 & mu;g/ml, respectively; and the MIC50 and MIC90 results for itraconazole, posaconazole, and isavuconazole were 8 and 8, 2 and 2, and 2 and 8 & mu;g/ml, respectively. In vitro data showed that amphotericin B was the most effective antifungal against most species. The commercially available ready-to-use minimum inhibitory concentration plates are user-friendly for performing antifungal susceptibility, which may be useful in choosing appropriate regimens and monitoring emerging resistance.
引用
收藏
页数:8
相关论文
共 50 条
[41]   Survival and prognostic factors in rhino-orbito-cerebral mucormycosis: A 3-year cohort study [J].
Zia, Zahra ;
Sajadi, Mohamad Javad ;
Bazrafshan, Hanieh ;
Khademi, Behzad ;
Janipour, Masoud .
SCIENTIFIC REPORTS, 2025, 15 (01)
[42]   Role of COVID 19 Inflammatory Markers in Rhino-Orbito-Cerebral Mucormycosis: A Case Study in Predisposed Patients at a Designated Nodal Centre [J].
Goddanti, Nitya ;
Reddy, Y. Mounika ;
Kumar, M. Kiran ;
Rajesh, M. ;
Reddy, L. Sudarshan .
INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2022, 74 (SUPPL 2) :3498-3504
[43]   First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus [J].
Diwakar, Jyoti ;
Samaddar, Arghadip ;
Konar, Subhas Kanti ;
Bhat, Maya Dattatraya ;
Manuel, Emma ;
Veenakumari, H. B. ;
Nandeesh, B. N. ;
Parveen, Asmiya ;
Hajira, Sadiya Noor ;
Srinivas, Dwarakanath ;
Nagarathna, S. .
JOURNAL DE MYCOLOGIE MEDICALE, 2021, 31 (04)
[44]   Role of COVID 19 Inflammatory Markers in Rhino-Orbito-Cerebral Mucormycosis: A Case Study in Predisposed Patients at a Designated Nodal Centre [J].
Nitya Goddanti ;
Y. Mounika Reddy ;
M. Kiran Kumar ;
M. Rajesh ;
L. Sudarshan Reddy .
Indian Journal of Otolaryngology and Head & Neck Surgery, 2022, 74 :3498-3504
[45]   Fatality Chooses Its Path Through the Orbit: A Study of Rhino-Orbito-Cerebral Mucormycosis as a Complication of COVID-19 Infection [J].
Mehfooz, Samreen ;
Mehrotra, Neelima ;
Usmani, Tarim ;
Raj, Vivek .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
[46]   Perioperative anesthesia challenges and outcomes of patients with Rhino-Orbito-Cerebral Mucormycosis during the second wave of COVID-19 pandemic: An observational study [J].
Kumari, Kamlesh ;
Rathod, Darshana ;
Meshram, Tanvi ;
Mohammed, Sadik ;
Raju, Sachith ;
Sharma, Ankur ;
Chaudhary, Bikram ;
Bhatia, Pradeep .
JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2023, 39 (04) :615-621
[47]   A pictorial review of imaging manifestations of rhino-orbito-cerebral mucormycosis–emerging threat in COVID pandemic [J].
Ankita Aggarwal ;
Nishu Raj ;
Krishna Bhardwaj ;
Ritu Nair Misra ;
Amita Malik ;
Sunil Bajaj .
Egyptian Journal of Radiology and Nuclear Medicine, 53
[48]   Orbital Exenteration in Rhino-Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring System [J].
Shah, Kshitij ;
Dave, Varun ;
Bradoo, Renuka ;
Shinde, Chhaya ;
Prathibha, M. .
INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2019, 71 (02) :259-265
[49]   Orbital Exenteration in Rhino-Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring System [J].
Kshitij Shah ;
Varun Dave ;
Renuka Bradoo ;
Chhaya Shinde ;
M. Prathibha .
Indian Journal of Otolaryngology and Head & Neck Surgery, 2019, 71 :259-265
[50]   Immunosuppression is a Double-Edged Sword in COVID-19 Treatment: a Case Report of Rhino-Orbito-Cerebral Mucormycosis [J].
Sedaghattalab, Moslem ;
Bagheri, Tahmineh ;
Doustimotlagh, Amir H. .
CLINICAL LABORATORY, 2022, 68 (07) :1484-1487